N-[(E)-benzylideneamino]-3-ethoxyquinoxalin-2-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-[(E)-benzylideneamino]-3-ethoxyquinoxalin-2-amine
• 化学式: C₁₇H₁₆N₄O
• 分子量: 292.33
• InChiKey: QUWLOIORNKYELO-LDADJPATSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors
  申请人：Niu Deqiang

  公开号：US20070299078A1

  公开（公告）日：2007-12-27

  The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及化合物，包括式I的化合物，或其药用可接受的盐、酯或前药：这些化合物抑制丝氨酸蛋白酶活性，特别是丝氨酸蛋白酶活性，尤其是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且还可用作抗病毒药剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给予含有本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
• QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS
  申请人：Niu Deqiang

  公开号：US20090005387A1

  公开（公告）日：2009-01-01

  The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• US7176208B2
  申请人：——

  公开号：US7176208B2

  公开（公告）日：2007-02-13
• US7368452B2
  申请人：——

  公开号：US7368452B2

  公开（公告）日：2008-05-06
• US7635683B2
  申请人：——

  公开号：US7635683B2

  公开（公告）日：2009-12-22